FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1543261323> ?p ?o ?g. }

• W1543261323 endingPage "895" @default.
• W1543261323 startingPage "886" @default.
• W1543261323 abstract "The objective of this study was to investigate the impact of rivastigmine therapy on attention, apathy, anxiety and agitation in patients with mild-to-moderate Alzheimer's disease (AD) in a real-world clinical setting. Patients with mild-to-moderate AD were enrolled in the study by physicians across Canada. They were treated with open-label rivastigmine (dose at the discretion of the prescribing physicians) for a period of 6 months. Changes from baseline in attention, apathy, anxiety and agitation were assessed using an abbreviated Clinician's Global Impression of Change at 3- and 6-month visits. The Mini Mental State Examination (MMSE) was also used at these visits. Use and changes in use of psychotropic medications were recorded, as were changes in caregiver burden. Analyses of subgroups (outpatients vs. institutionalised patients) were also performed. A total of 2119 patients were enrolled in the study by 375 physicians. At baseline, 91% had deficits in attention, 85.4% had symptoms of anxiety, 78.5% exhibited apathy and 70.1% showed agitation. At 6 months, 67.5% of evaluable patients had improved on the symptom of attention, while 62.3%, 62.6% and 56.0% had improvements in anxiety, apathy and agitation respectively. The percentages with improvements were higher in the institutional subgroup than among outpatients. There was an overall mean improvement of 1.1 points on the MMSE at 6 months. Approximately four times as many caregivers reported a reduced burden than an increased burden at 6 months (40.3% vs. 10.3%). The majority of patients treated with rivastigmine experienced improvements in attention, anxiety, apathy and agitation. These real-life findings further demonstrate the proven efficacy of rivastigmine in patients with mild-to-moderate AD." @default.
• W1543261323 created "2016-06-24" @default.
• W1543261323 creator A5004968642 @default.
• W1543261323 creator A5008234768 @default.
• W1543261323 creator A5022197187 @default.
• W1543261323 creator A5080506802 @default.
• W1543261323 date "2007-05-10" @default.
• W1543261323 modified "2023-10-14" @default.
• W1543261323 title "EXACT: rivastigmine improves the high prevalence of attention deficits and mood and behaviour symptoms in Alzheimer's disease*" @default.
• W1543261323 cites W125227749 @default.
• W1543261323 cites W144495947 @default.
• W1543261323 cites W193198674 @default.
• W1543261323 cites W1968814297 @default.
• W1543261323 cites W1985528178 @default.
• W1543261323 cites W1990854180 @default.
• W1543261323 cites W2001950185 @default.
• W1543261323 cites W2007522537 @default.
• W1543261323 cites W2021656561 @default.
• W1543261323 cites W2024673430 @default.
• W1543261323 cites W2033188343 @default.
• W1543261323 cites W2049683617 @default.
• W1543261323 cites W2062122326 @default.
• W1543261323 cites W2070566742 @default.
• W1543261323 cites W2076676029 @default.
• W1543261323 cites W2083677744 @default.
• W1543261323 cites W2085959837 @default.
• W1543261323 cites W2124214624 @default.
• W1543261323 cites W2140719894 @default.
• W1543261323 cites W2142903182 @default.
• W1543261323 cites W2147988536 @default.
• W1543261323 cites W2169882533 @default.
• W1543261323 cites W2209078744 @default.
• W1543261323 cites W4252912267 @default.
• W1543261323 doi "https://doi.org/10.1111/j.1742-1241.2007.01387.x" @default.
• W1543261323 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1974793" @default.
• W1543261323 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17504350" @default.
• W1543261323 hasPublicationYear "2007" @default.
• W1543261323 type Work @default.
• W1543261323 sameAs 1543261323 @default.
• W1543261323 citedByCount "30" @default.
• W1543261323 countsByYear W15432613232012 @default.
• W1543261323 countsByYear W15432613232013 @default.
• W1543261323 countsByYear W15432613232014 @default.
• W1543261323 countsByYear W15432613232015 @default.
• W1543261323 countsByYear W15432613232016 @default.
• W1543261323 countsByYear W15432613232018 @default.
• W1543261323 countsByYear W15432613232019 @default.
• W1543261323 countsByYear W15432613232021 @default.
• W1543261323 countsByYear W15432613232022 @default.
• W1543261323 crossrefType "journal-article" @default.
• W1543261323 hasAuthorship W1543261323A5004968642 @default.
• W1543261323 hasAuthorship W1543261323A5008234768 @default.
• W1543261323 hasAuthorship W1543261323A5022197187 @default.
• W1543261323 hasAuthorship W1543261323A5080506802 @default.
• W1543261323 hasBestOaLocation W15432613231 @default.
• W1543261323 hasConcept C118552586 @default.
• W1543261323 hasConcept C126322002 @default.
• W1543261323 hasConcept C139719470 @default.
• W1543261323 hasConcept C142724271 @default.
• W1543261323 hasConcept C162324750 @default.
• W1543261323 hasConcept C187212893 @default.
• W1543261323 hasConcept C204787440 @default.
• W1543261323 hasConcept C27081682 @default.
• W1543261323 hasConcept C2776000289 @default.
• W1543261323 hasConcept C2776332859 @default.
• W1543261323 hasConcept C2776509080 @default.
• W1543261323 hasConcept C2776867660 @default.
• W1543261323 hasConcept C2779134260 @default.
• W1543261323 hasConcept C2779483572 @default.
• W1543261323 hasConcept C2780733359 @default.
• W1543261323 hasConcept C2780904820 @default.
• W1543261323 hasConcept C558461103 @default.
• W1543261323 hasConcept C71924100 @default.
• W1543261323 hasConceptScore W1543261323C118552586 @default.
• W1543261323 hasConceptScore W1543261323C126322002 @default.
• W1543261323 hasConceptScore W1543261323C139719470 @default.
• W1543261323 hasConceptScore W1543261323C142724271 @default.
• W1543261323 hasConceptScore W1543261323C162324750 @default.
• W1543261323 hasConceptScore W1543261323C187212893 @default.
• W1543261323 hasConceptScore W1543261323C204787440 @default.
• W1543261323 hasConceptScore W1543261323C27081682 @default.
• W1543261323 hasConceptScore W1543261323C2776000289 @default.
• W1543261323 hasConceptScore W1543261323C2776332859 @default.
• W1543261323 hasConceptScore W1543261323C2776509080 @default.
• W1543261323 hasConceptScore W1543261323C2776867660 @default.
• W1543261323 hasConceptScore W1543261323C2779134260 @default.
• W1543261323 hasConceptScore W1543261323C2779483572 @default.
• W1543261323 hasConceptScore W1543261323C2780733359 @default.
• W1543261323 hasConceptScore W1543261323C2780904820 @default.
• W1543261323 hasConceptScore W1543261323C558461103 @default.
• W1543261323 hasConceptScore W1543261323C71924100 @default.
• W1543261323 hasIssue "6" @default.
• W1543261323 hasLocation W15432613231 @default.
• W1543261323 hasLocation W15432613232 @default.
• W1543261323 hasLocation W15432613233 @default.
• W1543261323 hasLocation W15432613234 @default.
• W1543261323 hasOpenAccess W1543261323 @default.
• W1543261323 hasPrimaryLocation W15432613231 @default.

• next